带状疱疹由水痘-带状疱疹病毒（varicella-zoster virus）再激活引起，研究表明其可能加速大脑衰老并增加痴呆风险。一个案例涉及一名63岁的病毒免疫学讲师，其认知能力在4年内持续下降，随后被发现是病毒再激活并通过抗病毒药物阿昔洛韦治疗后恢复。流行病学数据进一步表明该病毒的长期神经影响可能被低估。带状疱疹还与严重神经痛相关，并与脑部炎症和认知障碍之间存在联系。

疫苗研究提供了重要统计证据。2025年斯坦福大学研究表明，带状疱疹疫苗可能预防约五分之一的新发痴呆病例。历史数据表明，在美国1995年开始儿童水痘疫苗接种前，超过90%的儿童会感染该病毒，随后病毒在周围神经系统中潜伏数十年。随着年龄增长，免疫细胞抑制病毒的能力下降，导致再激活。研究还发现带状疱疹与认知下降和痴呆存在关联，因此疫苗接种和加强针可能通过防止再激活来保护大脑健康。

病毒再激活还与其他神经风险相关。研究显示，带状疱疹后一个月内中风风险增加80%，一年后仍高出20%。病毒可能通过感染脑动脉并引发慢性炎症导致血管性痴呆，并可能同时触发另一种潜伏病毒HSV-1再激活，从而加剧神经损伤。当前带状疱疹疫苗通常建议50岁以上人群接种，但研究人员提出可能需要更早接种并进行多次加强。随着本世纪65岁以上人口预计将翻倍，预防病毒再激活被认为可能在未来几十年降低认知衰退和痴呆负担。

Shingles results from reactivation of the varicella-zoster virus, and research suggests it may accelerate brain aging and increase dementia risk. One case involved a 63-year-old viral immunologist whose cognition declined over four years before tests revealed viral reactivation; treatment with the antiviral acyclovir restored his cognitive function. Epidemiological evidence indicates that the neurological burden of the virus may be underestimated. Shingles has long been associated with severe nerve pain but is increasingly linked to brain inflammation and cognitive impairment.

Vaccine studies provide significant statistical evidence. A 2025 Stanford University study suggested that shingles vaccination could prevent about one in five new dementia cases. Historical data show that before the United States introduced routine childhood chickenpox vaccination in 1995, more than 90% of children acquired the virus, which then remained dormant in the peripheral nervous system for decades. As immune function declines with age, the virus can reactivate. Studies also link shingles episodes with self-reported cognitive decline and dementia, suggesting vaccination and booster shots may protect brain health by preventing reactivation.

Viral reactivation is also associated with additional neurological risks. Research shows stroke risk rises by 80% in the first month after shingles and remains 20% higher one year later. The virus may infect cerebral arteries and trigger chronic inflammation, contributing to vascular dementia, and may also reactivate another latent virus, HSV-1, amplifying neurological damage. Shingles vaccination is currently recommended for adults over 50, but researchers propose earlier vaccination and multiple boosters. With the population over age 65 expected to double this century, preventing viral reactivation could reduce future rates of cognitive decline and dementia.